Cell Therapy News Volume 22.35 | Oct 4 2021

    By
    Justin.choi
    -
    0
    40







    2021-10-04 | CTN 22.35


    Cell Therapy News by STEMCELL Technologies
    Vol. 22.35 – 4 October, 2021
    TOP STORY

    Autologous Transplant versus Chimeric Antigen Receptor T-Cell Therapy for Relapsed DLBCL in Partial Remission

    Researchers identified adult diffuse large B-cell lymphoma (DLBCL) patients who received either an auto-hematopoietic cell transplant or CAR-T treatment with axicabtagene ciloleucelwhile in a partial remission by CT or PET scan.
    [Blood]

    Abstract
    Free E-Book: Genome Editing Applications for Disease Modeling and Cell Therapy.
    PUBLICATIONSRanked by the impact factor of the journal

    PI3Kγδ Inhibitor plus Radiation Enhances the Antitumor Immune Effect of PD-1 Blockade in Syngenic Murine Breast Cancer and Humanized Patient-Derived Xenograft Model

    Murine breast cancer cells were grown in both immune-competent and -deficient BALB/c mice, and tumors were irradiated by three fractions of 24 Gy. A PD-1 blockade and a phosphoinositide 3-kinase (PI3K)γδ inhibitor were then administered every other day for two weeks.
    [European Journal of Cancer]

    Abstract

    Assessing Patient Perception of Risk in Ocular Stem Cell Therapies

    Scientists assessed risk tolerance using an in-person survey of 178 patients at an academic eye center. Risk of malignancy served as a hypothetical, readily understood, and serious adverse event to be considered in trade for potential visual improvement from a stem cell-derived treatment.
    [Stem Cell Reports]

    Full Article

    Outcomes and Toxicity of Allogeneic Hematopoietic Cell Transplantation in Chronic Myeloid Leukemia Patients Previously Treated with Second-Generation Tyrosine Kinase Inhibitors: A Prospective Non-Interventional Study from the Chronic Malignancy Working Party of the EBMT

    Investigators presented the results of a prospective non-interventional study performed by the EBMT on 383 consecutive chronic myeloid leukemia patients previously treated with dasatinib or nilotinib undergoing allogeneic hematopoietic cell transplantation from 2009 to 2013.
    [Bone Marrow Transplantation]

    Full Article

    B Cell Depletion Abrogates Immune Mediated Cytopenia and Rejection of Cord Blood Transplantation in Hurler Syndrome

    Researchers studied 57 patients in two centers who received myeloablative conditioning for cord blood transplant in Hurler syndrome, and reported a significant improvement in event-free survival with reduced incidence of graft failure and without any evidence of immune-mediated cytopenia in those patients that had received rituximab.
    [Bone Marrow Transplantation]

    Full Article

    Maintenance Therapy after Second Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: A CIBMTR Analysis

    Scientists explored the effect of maintenance therapy on outcomes after salvage second autologous hematopoietic cell transplant using the Center for International Blood and Marrow Transplant Research registry.
    [Bone Marrow Transplantation]

    Abstract

    Novel TCR-like CAR-T Cells to Target an HLA*0201 Restricted Epitope from the Cancer-Testis Antigen SSX2 Display Strong Activity against Acute Myeloid Leukemia

    Investigators developed a T cell Receptor-like antibody that binds SSX2 peptide 41-49 in the context of HLA-A*-0201.
    [Molecular Therapy-Methods & Clinical Development]

    Abstract

    Conditional Control of Chimeric Antigen Receptor T Cell Activity through a Destabilizing Domain Switch and Its Chemical Ligand

    The authors revealed a strategy to modulate CAR T-cell activity at the protein level by employing Escherichia coli dihydrofolate reductase and trimethoprim as a chemical switch system.
    [Cytotherapy]

    Abstract

    Stem Cells from Human Exfoliated Deciduous Teeth Affect Mitochondria and Reverse Cognitive Decline in a Senescence-Accelerated Mouse Prone 8 Model

    SHEDs were cultured in vitro and injected into AD SAMP8 mice by caudal vein, and SHEDs labeled via synthetic dye showed in vivo migration to the head.
    [Cytotherapy]

    Abstract

    A Phase I/II Dose-Escalation Multi-Center Study to Evaluate the Safety of Infusion of Natural Killer Cells or Memory T Cells as Adoptive Therapy in Coronavirus Pneumonia and/or Lymphopenia: RELEASE Study Protocol

    In the Phase I trial, 18 patients with COVID-19-related pneumonia and/or lymphopenia with no oxygen requirement or with an oxygen need of less than or equal to 2.5 liters per minute in nasal cannula were assigned to two arms, based on the biology of the donor and the patient.
    [Trials]

    Full Article
    Be sure the cells you’re gene editing are still HSPCs with StemSpan™ SFEM II culture medium.
    REVIEWS

    Genome Editing in Large Animal Models

    Large animal models, including dogs, pigs and non-human primates, bear greater resemblance to human anatomy, immunology and lifespan, and can be studied over longer timescales with clinical dosing regimens that are more relevant to humans.
    [Molecular Therapy]

    AbstractGraphical Abstract

    Considerations for the Delivery of STING Ligands in Cancer Immunotherapy

    In order to achieve successful transfection and protection from enzymatic degradation there is a need for a suitable carrier for cGAMP. Scientists described currently reported carriers for cGAMP, and correlate their characteristics to the effect they cause.
    [Journal of Controlled Release]

    Full ArticleGraphical Abstract
    INDUSTRY AND POLICY NEWS

    Atara Biotherapeutics and Pierre Fabre Enter Strategic Collaboration to Commercialize Tabelecleucel (Tab-Cel®)

    Atara Biotherapeutics, Inc. and Pierre Fabre announced an exclusive commercialization agreement for tabelecleucel in Europe, Middle East, Africa, and other select emerging markets for Epstein-Barr virus-positive cancers.
    [Atara Biotherapeutics, Inc.]

    Press Release

    US FDA Approves Kite’s Tecartus® as the First and Only CAR T for Adults with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

    Kite, a Gilead Company announced the FDA has granted approval for Tecartus® for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
    [Kite]

    Press Release
    FEATURED EVENT

    American Association of Blood Banks (AABB)

    October 17 – 19, 2021
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Assistant Editor – Cytotherapy

    The International Society for Cell & Gene Therapy – Vancouver, British Columbia, Canada

    Postdoctoral Scientist – Drug Discovery Sciences

    Boehringer Ingelheim – Biberach, Germany

    Research Assistant – Regenerative Medicine for the Biliary System

    University of Cambridge – Cambridge, England, United Kingdom

    Postdoctoral Position – Stem Cells and Disease Modeling

    King Abdullah University of Science and Technology – Thuwal, Saudi Arabia

    Head of Laboratory – Cellular Therapies

    NHS Blood and Transplant – Oxford, England, United Kingdom

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cell Therapy News Twitter